Lilly (LLY) obesity pill reduces cardiovascular risks in trial
Published on 4/16/2026
AI Summary
Eli Lilly (LLY) announced that its Foundayo obesity pill met its trial goals by reducing the risk of major cardiovascular events by 16% in over 2,700 adults with type 2 diabetes. Compared to insulin glargine, patients taking Foundayo experienced a 57% lower risk of death from any cause. Additionally, those on Foundayo had greater reductions in blood sugar and weight, unlike patients on insulin glargine who gained weight. Eli Lilly plans to seek U.S. approval for Foundayo for type 2 diabetes by the end of Q2.
Related News
Health
WHO Chief Calls for Funding in Congo Ebola Response Efforts
May 30
Health
Replimune (REPL) Drug Receives New Chance After White House Action
May 30
Healthcare
CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
May 28
Health
Cancer Treatment Costs Could Rise Significantly in Future Outlook
May 27